MAKSIM MAMONKIN to T-Lymphocytes
This is a "connection" page, showing publications MAKSIM MAMONKIN has written about T-Lymphocytes.
Connection Strength
3.803
-
Splendid isolation. Blood. 2023 06 01; 141(22):2665-2666.
Score: 0.461
-
Reversal of exhaustion in engineered T cells. Science. 2021 04 02; 372(6537):34-35.
Score: 0.397
-
Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
Score: 0.377
-
Generation of Chimeric Antigen Receptor T Cells Using Gammaretroviral Vectors. Methods Mol Biol. 2020; 2086:119-130.
Score: 0.364
-
Analysis of CAR-Mediated Tonic Signaling. Methods Mol Biol. 2020; 2086:223-236.
Score: 0.364
-
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res. 2018 01; 6(1):47-58.
Score: 0.313
-
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
Score: 0.304
-
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
Score: 0.124
-
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
Score: 0.122
-
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
Score: 0.110
-
Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There? Cancer J. 2021 Mar-Apr 01; 27(2):176-181.
Score: 0.099
-
Taking T-Cell Oncotherapy Off-the-Shelf. Trends Immunol. 2021 03; 42(3):261-272.
Score: 0.098
-
Detonating T-ALL. Blood. 2020 09 10; 136(11):1218-1219.
Score: 0.095
-
CRISPR-Edited Immune Effectors: The End of the Beginning. Mol Ther. 2020 04 08; 28(4):995-996.
Score: 0.092
-
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26.
Score: 0.078
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.076
-
[CAR T-cell therapy: Balance of efficacy and safety]. Mol Biol (Mosk). 2017 Mar-Apr; 51(2):274-287.
Score: 0.075
-
Exhausting alloreactivity of donor-derived CAR T cells. Nat Med. 2017 02 07; 23(2):147-148.
Score: 0.074
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
Score: 0.072
-
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells. Sci Adv. 2025 Jan 10; 11(2):eadq8114.
Score: 0.032
-
Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Aug; 26(8):858-868.
Score: 0.030
-
Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy. Cytotherapy. 2022 03; 24(3):282-290.
Score: 0.026
-
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
Score: 0.021